European commercialization may look daunting at first, 30 EEA countries plus the UK and Switzerland, a population of 370 million, multiple regulatory systems, diverse reimbursement environments, labor laws, and a rich mix of languages and cultures.

That’s why this session is essential for any CEO weighing Europe as a strategic option. While the challenges are real, the rewards of building a presence can be extraordinary—expanding patient access beyond the U.S. and significantly increasing market value. In this episode, senior biotech leaders share their current experiences and insights, covering critical decisions such as choosing a European HQ location, setting rollout timing and cadence, and, most importantly, avoiding the bear traps along the way.